a year ago
BCRX
AnalystsJonathan WollebenJonathan Wolleben's Stock Forecasts
AnalystsJonathan Wolleben
Analyst Ranking
Top 3%
#139 out of 5550 analysts
Average Return
+18.85%
Win Rate
49%141 out of 289
Risk vs Reward
Poor
Good
Jonathan Wolleben's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Mbx Biosciences IncMBX | +424.08% | $6.27 | $32.86 | 2025-04-10 - 2026-04-09 | Buy |
Dbv Technologies SaDBVT | +408.60% | $4.30 | $21.87 | 2025-03-04 - 2026-03-03 | Buy |
Dbv Technologies SaDBVT | +397.39% | $3.45 | $17.16 | 2024-12-10 - 2025-12-09 | Buy |
Madrigal Pharmaceuticals IncMDGL | +365.01% | $64.44 | $299.65 | 2022-05-10 - 2023-05-09 | Buy |
Dbv Technologies SaDBVT | +242.25% | $4.97 | $17.01 | 2025-01-10 - 2026-01-09 | Buy |
Jonathan Wolleben Analyst Color
Get additional color on Jonathan Wolleben's coverage of popular stocks
a year ago
BCRX
2 years ago
SPOT
Jonathan Wolleben's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Dbv Technologies SaDBVT | 20 | Buy | $47.00 | +395.26% | Maintains | 4 days ago |
Opus Genetics IncIRD | 4 | Buy | $17.00 | +363.22% | Reiterates | 17 days ago |
Biomea Fusion IncBMEA | 2 | Buy | $7.00 | +995.46% | Reiterates | 19 days ago |
Sagimet Biosciences IncSGMT | 12 | Buy | $27.00 | +172.18% | Maintains | a month ago |
Spruce Biosciences IncSPRB | 12 | Buy | $144.00 | +210.41% | Reiterates | a month ago |
Irulya Therapeutics IncIRLA | 4 | Buy | $77.00 | +133.69% | Upgrades | a month ago |
Pharvaris NvPHVS | 15 | Buy | $79.00 | +135.61% | Maintains | 2 months ago |
Structure Therapeutics IncGPCR | 14 | Buy | $110.00 | +402.97% | Reiterates | 2 months ago |
Mirum Pharmaceuticals IncMIRM | 18 | Buy | $137.00 | +61.18% | Reiterates | 2 months ago |
Annexon IncANNX | 2 | Hold | N/A | N/A | Upgrades | 3 months ago |
Rhythm Pharmaceuticals IncRYTM | 10 | Buy | $160.00 | +72.84% | Maintains | 3 months ago |
Crinetics Pharmaceuticals IncCRNX | 22 | Buy | $95.00 | +11.83% | Reiterates | 5 months ago |
Sionna Therapeutics IncSION | 2 | Buy | $63.00 | +1,527.91% | Reiterates | 5 months ago |
Altimmune IncALT | 14 | Buy | $11.00 | +439.22% | Maintains | 6 months ago |
Kalaris Therapeutics IncKLRS | 2 | Buy | $25.00 | +1,131.53% | Maintains | 6 months ago |
Mbx Biosciences IncMBX | 2 | Buy | $86.00 | +53.93% | Maintains | 6 months ago |
Biocryst Pharmaceuticals IncBCRX | 11 | Buy | $28.00 | +230.58% | Maintains | 6 months ago |
Protagonist Therapeutics IncPTGX | 15 | Buy | $137.00 | -5.42% | Maintains | 6 months ago |
Kalvista Pharmaceuticals IncKALV | 7 | Buy | $28.00 | +3.70% | Maintains | 7 months ago |
Madrigal Pharmaceuticals IncMDGL | 13 | Buy | $745.00 | +73.11% | Maintains | 9 months ago |
Savara IncSVRA | 10 | Buy | $10.00 | +107.47% | Maintains | a year ago |
Astria Therapeutics IncATXS | 4 | Hold | N/A | N/A | Downgrades | a year ago |
Ocular Therapeutix IncOCUL | 16 | Buy | $29.00 | N/A | Maintains | a year ago |
Larimar Therapeutics IncLRMR | 13 | Buy | $18.00 | N/A | Reiterates | a year ago |
Proqr Therapeutics NvPRQR | 6 | Buy | $8.00 | N/A | Reiterates | a year ago |
Skye Bioscience IncSKYE | 3 | Buy | $120.00 | N/A | Reiterates | a year ago |
Aura Biosciences IncAURA | 9 | Buy | $19.00 | N/A | Reiterates | a year ago |
Clearside Biomedical IncCLSDQ | 11 | Buy | $75.00 | N/A | Reiterates | a year ago |
Hilton Grand Vacations IncHGV | 1 | Buy | $50.00 | N/A | Maintains | 2 years ago |
Costar Group IncCSGP | 1 | Buy | $90.00 | N/A | Reiterates | 2 years ago |
Airbnb IncABNB | 1 | Hold | N/A | N/A | Reiterates | 2 years ago |
Spotify Technology SaSPOT | 1 | Buy | $485.00 | N/A | Downgrades | 2 years ago |
Allakos IncALLK | 6 | Buy | $3.00 | N/A | Reiterates | 2 years ago |
Rallybio CorpRLYB | 11 | Buy | $64.00 | N/A | Reiterates | 3 years ago |
Warner Music Group CorpWMG | 1 | Buy | $24.00 | N/A | Maintains | 3 years ago |
Strongbridge Biopharma PLCSBBP | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.